Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-Week results from the Dutch BioDay registry,

Lieneke F.M. Ariëns*, Jorien van der Schaft, Lotte S. Spekhorst, Daphne S. Bakker, Geertruida L.E. Romeijn, Tessa A. Kouwenhoven, Marijke Kamsteeg, Angelique N. Voorberg, Albert J. Oosting, Ilona de Ridder, Annemieke Sloeserwij, Inge Haeck, Judith L. Thijs, Marie L.A. Schuttelaar, Marjolein S. de Bruin-Weller*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

69 Downloads (Pure)

Abstract

Background
Real-life data on long-term effectiveness and safety of dupilumab in atopic dermatitis patients are limited.

Objective
To study 52-week effectiveness and safety of dupilumab in a prospective multicenter cohort of adult patients with treatment-refractory atopic dermatitis.

Methods
Patients treated with dupilumab and participating in the Dutch BioDay registry were included. Clinical effectiveness and safety were evaluated.

Results
Two hundred ten atopic dermatitis patients were included. Mean percentage change in Eczema Area and Severity Index score after 16 weeks was –70.0% (standard deviation 33.2%) and further decreased to –76.6% (standard deviation 30.6%) by week 52. A greater than or equal to 75% improvement in the score was achieved by 59.9% of individuals by week 16 and by 70.3% by week 52. The most reported adverse effect was conjunctivitis (34%). Limited patients (17; 8.1%) discontinued dupilumab treatment.

Limitations
Because of the lack of a control group and observational design, factors of bias may have been induced.

Conclusion
Treatment with dupilumab resulted in a rapid improvement in clinical outcome measures, and effectiveness further improved during the 52-week follow-up period.
Original languageEnglish
Pages (from-to)e279-e280
Number of pages10
JournalJournal of the American Academy of Dermatology
Volume84
Issue number4
DOIs
Publication statusPublished - Apr-2021

Cite this